FTY720 immunosuppression for kidney transplant recipients

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Tan, Jiying ^a   Wu, Yu Min ^a   Ma, Bin ^a   Pang, Hong Li ^a   Tian, Jin Hui ^a   Jiang, Lei ^a   Bai, Zheng Gang ^a   Li, Youping ^b  

^a LANZHOU UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTED ARTICLE;

EID: 85040458645     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008010.pub2     Document Type: Article

References (26)

1. Brinkmann V, Pinschewer DD, Feng L, Chen S. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001;72(5):764-9. [MEDLINE: 11571432]
2. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. American Journal of Transplantation 2004;4(7):1019-25. [MEDLINE: 15196057]
3. Budde K, Schutz M, Glander P, Peters H, Waiser J, Liefeldt L, et al.FTY720 (fingolimod) in renal transplantation. Clinical Transplantation 2006;20(17):17-24. [MEDLINE: 17100697]
4. Chiba K, Hoshino Y, Suzuki C, Masubuchi Y, Yanagawa Y, Ohtsuki M, et al.FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplantation Proceedings 1996;28(2):1056-9. [MEDLINE: 8623225]
5. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, et al.Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. Journal of Antibiotics 1994;47(2):208-15. [MEDLINE: 8150717]
6. Halloran PF. Immunosuppressive drugs for kidney transplantation. New England Journal of Medicine 2004;351(26):2715-29. [MEDLINE: 15616206]
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
8. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008. Available from www.cochrane-handbook.org.
9. Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003;76(7):1079-84. [MEDLINE: 14557756]
10. Kamoun M. Cellular and molecular parameters in human renal allograft rejection. Clinical Biochemistry 2001;34(1):29-34. [MEDLINE: 11239512]
11. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org.
12. United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed May 2009).
13. Milford EL. Chronic renal allograft loss. Current Opinion in Nephrology & Hypertension 1994;3(4):475-9. [MEDLINE: 8076154]
14. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. New England Journal of Medicine 2003;349(24):2326-33. [MEDLINE: 14668458]
15. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. Journal of Immunology 2000;164(11):5761-70. [MEDLINE: 10820254]
16. Ramanathan V, Goral S, Helderman JH. Renal transplantation. Seminars in Nephrology 2001;21(2):213-9. [MEDLINE: 11245782]
17. Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC. Cochrane Renal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 3. Art. No.: RENAL (accessed July 2009).
18. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, et al.FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. American Journal of Transplantation 2006 Dec;6(12):2912-21. [MEDLINE: 17061999]
19. Stepkowski SM, Wang M, Qu X, Yu J, Okamoto M, et al.Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival. Transplantation Proceedings 1998 Aug;30(5):2214-6. [MEDLINE: 9723445]
20. Suzuki S, Enosawa S, Kakefuda T, Amemiya H, Hoshino Y, Chiba K. Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720. Transplantation Proceedings 1996;28(3):1375-6. [MEDLINE: 8658701]
21. Suzuki S, Enosawa S, Kakefuda T, Shinomiya T, Amari M, Naoe S, et al.A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996;61(2):200-5. [MEDLINE: 8600623]
22. Tedesco-Silva H, Mourad G, Kahan BC, Boira JG, Weimar W, Mulgaonkar S, et al.FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2004;77(12):1826-33. [MEDLINE: 15940045]
23. Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, et al.Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006;82(12):1689-97. [MEDLINE: 17198261]
24. Wang ME, Tejpal N, Qu X, Yu J, Okamoto M, Stepkowski SM, et al.Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus. Transplantation 1998;65(7):899-905. [MEDLINE: 9565092]
25. Xu M, Pirenne J, Antoniou EA, Afford SC, D'Silva M, McMaster P. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. Transplant International 1998;11(4):288-94. [MEDLINE: 9704394]
26. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. Journal of Immunology 1998;160(11):5493-9. [MEDLINE: 9605152]